HK1255850A1 - 5-ht2c受体激动剂和组合物及使用方法 - Google Patents

5-ht2c受体激动剂和组合物及使用方法 Download PDF

Info

Publication number
HK1255850A1
HK1255850A1 HK18114926.0A HK18114926A HK1255850A1 HK 1255850 A1 HK1255850 A1 HK 1255850A1 HK 18114926 A HK18114926 A HK 18114926A HK 1255850 A1 HK1255850 A1 HK 1255850A1
Authority
HK
Hong Kong
Prior art keywords
disorders
sleep
addiction
antipsychotic
methods
Prior art date
Application number
HK18114926.0A
Other languages
English (en)
Chinese (zh)
Inventor
Lehmann Juerg
Feichtinger Konrad
S. Ren Albert
Semple Graeme
Original Assignee
Arena Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc. filed Critical Arena Pharmaceuticals, Inc.
Publication of HK1255850A1 publication Critical patent/HK1255850A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18114926.0A 2015-07-31 2016-07-28 5-ht2c受体激动剂和组合物及使用方法 HK1255850A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31
US62/199,382 2015-07-31
PCT/US2016/044426 WO2017023679A1 (en) 2015-07-31 2016-07-28 5-ht2c receptor agonists and compositions and methods of use

Publications (1)

Publication Number Publication Date
HK1255850A1 true HK1255850A1 (zh) 2019-08-30

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114926.0A HK1255850A1 (zh) 2015-07-31 2016-07-28 5-ht2c受体激动剂和组合物及使用方法

Country Status (14)

Country Link
US (4) US10272094B2 (https=)
EP (1) EP3328835B1 (https=)
JP (1) JP6789578B2 (https=)
KR (1) KR20180031035A (https=)
CN (1) CN108137508B (https=)
AU (1) AU2016302755B2 (https=)
BR (1) BR112018001707A2 (https=)
CA (1) CA3002525A1 (https=)
EA (1) EA039412B1 (https=)
HK (1) HK1255850A1 (https=)
IL (1) IL257107B (https=)
MA (1) MA42527A (https=)
MX (1) MX375045B (https=)
WO (1) WO2017023679A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002525A1 (en) * 2015-07-31 2017-02-09 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US20220410894A1 (en) * 2021-06-29 2022-12-29 Tusimple, Inc. Systems and methods for operating an autonomous vehicle
CN118302349A (zh) 2021-10-14 2024-07-05 图森有限公司 用于操作自动驾驶车辆的系统和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JPWO2011071136A1 (ja) * 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US9556200B2 (en) * 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound
SG11201501894VA (en) * 2012-09-14 2015-04-29 Abbvie Inc Tricyclic quinoline and quinoxaline derivatives
CA3002525A1 (en) * 2015-07-31 2017-02-09 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
JP2018522025A (ja) 2018-08-09
CA3002525A1 (en) 2017-02-09
MX2018001380A (es) 2018-06-15
KR20180031035A (ko) 2018-03-27
NZ739883A (en) 2021-03-26
US20200383993A1 (en) 2020-12-10
US10624900B2 (en) 2020-04-21
US10272094B2 (en) 2019-04-30
US20200078368A1 (en) 2020-03-12
MA42527A (fr) 2021-04-07
IL257107A (en) 2018-03-29
EA039412B1 (ru) 2022-01-25
MX375045B (es) 2025-03-06
EP3328835A1 (en) 2018-06-06
CN108137508A (zh) 2018-06-08
IL257107B (en) 2021-03-25
AU2016302755A1 (en) 2018-03-15
EP3328835B1 (en) 2022-10-12
BR112018001707A2 (pt) 2018-09-18
EA201890402A1 (ru) 2018-09-28
JP6789578B2 (ja) 2020-11-25
US11395824B2 (en) 2022-07-26
US20230055376A1 (en) 2023-02-23
CN108137508B (zh) 2021-08-27
WO2017023679A1 (en) 2017-02-09
US20180214455A1 (en) 2018-08-02
AU2016302755B2 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
HK1255850A1 (zh) 5-ht2c受体激动剂和组合物及使用方法
MX2020005898A (es) Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
NZ750469A (en) 5-ht2c receptor agonists and compositions and methods of use
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
GEP20227387B (en) Methods and compositions for treating sleep apnea
EP3862362A3 (en) Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
TN2011000319A1 (en) Substituted quinazoline compounds
MA39763A (fr) Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
PL2049502T3 (pl) 2,4-Podstawione chinazoliny jako inhibitory kinazy lipidowej
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
MX2010007392A (es) Antagonistas de trpa1.
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2012093127A3 (en) Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
EP3856182A4 (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
WO2010091894A3 (en) Methods of treating hair related conditions
MX2011008549A (es) [1, 2, 4] triazolo [1 ,5 -a] piridinas como inhibidores de cinasa.
WO2009116037A3 (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
MY157319A (en) Inhibitors of protein tyrosine kinase activity
WO2009067243A3 (en) Modulation of cd40 expression
MX363632B (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
AR098271A1 (es) Agonistas del receptor 5-ht₂c
WO2007100631A3 (en) Compositions and methods for modulating cytokine production